IRIS Research and Development
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, IRIS Research and Development sits in the upper half of US sponsors by registered trial count (#4,885 of 15,742 sponsors by registered trial count).
IRIS Research and Development: 2 sponsored US clinical trials, 1 recruiting.
IRIS Research and Development sponsors 2 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 1 completed. 1 of these trials are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Granulomatosis With Polyangiitis, with 1 trials.
Mid-pack sponsor footprint
IRIS Research and Development is in the upper half of sponsors by trial count (#4,885 of 15,742 sponsors by registered trial count). Use the pipeline list and therapeutic areas to see what drives that mid-pack volume.
Open and recent trials
2 total, page 1 of 1
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 4 | 1 |
Therapeutic Areas
What is open in the IRIS Research and Development pipeline
1 recruiting of 2 indexed (50% open); 1 completed (50%).
Phase mix: 1 late (III/IV) vs 1 early (I/II) (balanced across stages).
Top condition: Granulomatosis With Polyangiitis (1 trial), 3 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
IRIS Research and Development: open-pipeline peers nationwide
Peers matched on 2 registered trials and 50% open enrollment, not the therapeutic-area sidebar.
IRIS Research and Development sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 2 trials (± recruiting share)
- 1200 Pharma · 2 trials · 50% recruiting
- 1ST Biotherapeutics · 2 trials · 50% recruiting
- 3 Waves Wellness · 2 trials · 0% recruiting
- 3EO Health · 2 trials · 0% recruiting
Sponsors near 50% open enrollment (± trial volume)
- 3ive Labs · 50% recruiting · 2 trials
- 60 Degrees Pharmaceuticals · 50% recruiting · 4 trials
- 7 Hills Pharma · 50% recruiting · 2 trials
- Abcentra · 50% recruiting · 2 trials
Related
What to do with this IRIS Research and Development page
2 registered trials is a research-attention snapshot, not an endorsement of IRIS Research and Development or any single study.
- 1 of IRIS Research and Development's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Granulomatosis With Polyangiitis is the condition IRIS Research and Development studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Granulomatosis With Polyangiitis trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. IRIS Research and Development pipeline card: 2 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.